PriceTargets.com logo

Orchestra BioMed - OBIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.50
  • Forecasted Upside: 129.96%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.61 As of 09/28/2023 03:20 PM ET
▼ -0.32 (-4.04%)

This chart shows the closing price for OBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Orchestra BioMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBIO

Analyst Price Target is $17.50
▲ +129.96% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Orchestra BioMed in the last 3 months. The average price target is $17.50, with a high forecast of $20.00 and a low forecast of $15.00. The average price target represents a 129.96% upside from the last price of $7.61.

This chart shows the closing price for OBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Orchestra BioMed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2023Chardan CapitalReiterated RatingBuy ➝ Buy$20.00Low
3/8/2023Lifesci CapitalReiterated RatingOutperformLow
2/24/2023Piper SandlerInitiated CoverageOverweight$15.00Low
2/7/2023Chardan CapitalInitiated CoverageBuy$20.00Low
(Data available from 9/28/2018 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Orchestra BioMed logo
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Read More

Today's Range

Now: $7.61
Low: $7.41
High: $7.92

50 Day Range

MA: $6.59
Low: $5.08
High: $10.77

52 Week Range

Now: $7.61
Low: $4.85
High: $23.39

Volume

38,099 shs

Average Volume

109,727 shs

Market Capitalization

$271.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Orchestra BioMed?

The following Wall Street analysts have issued stock ratings on Orchestra BioMed in the last year: Chardan Capital, Lifesci Capital, and Piper Sandler.
View the latest analyst ratings for OBIO.

What is the current price target for Orchestra BioMed?

2 Wall Street analysts have set twelve-month price targets for Orchestra BioMed in the last year. Their average twelve-month price target is $17.50, suggesting a possible upside of 130.0%. Chardan Capital has the highest price target set, predicting OBIO will reach $20.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $15.00 for Orchestra BioMed in the next year.
View the latest price targets for OBIO.

What is the current consensus analyst rating for Orchestra BioMed?

Orchestra BioMed currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OBIO will outperform the market and that investors should add to their positions of Orchestra BioMed.
View the latest ratings for OBIO.

What other companies compete with Orchestra BioMed?

Other companies that are similar to Orchestra BioMed include Cerus, AngioDynamics, Anika Therapeutics, Accuray and CVRx. Learn More about companies similar to Orchestra BioMed.

How do I contact Orchestra BioMed's investor relations team?

Orchestra BioMed's physical mailing address is 40 10TH AVENUE FLOOR 7, NEW YORK NY, 10014. The company's listed phone number is 646-597-6980 and its investor relations email address is [email protected]. The official website for Orchestra BioMed is orchestrabiomed.com. Learn More about contacing Orchestra BioMed investor relations.